Rasio utang jangka dawa marang modal immixbio.com (IMMX)

Immix Biopharma, Inc. (IMMX) liquidity depends on new issuances due to a lack of sales in oncotherapy. The long-term debt-to-equity ratio trend demonstrates leverage, where the 0.00 level captures recent values. Immix Biopharma, Inc. (IMMX) is implementing green chemistry principles for reagent disposal, although its environmental strategy is limited to third-party contractor certificates due to its virtual business model.

For Immix Biopharma, Inc. (IMMX), which is developing CAR-T therapy amidst fierce clinical competition, the ratio of liabilities exceeding one year to equity serves as an indicator of financial stability. This metric compares long-term borrowings with the business's own funds. The calculation allows for an assessment of the issuer's dependence on external financing when implementing costly research. Increasing leverage within this structure raises the risk of asset impairment as borrowing costs rise. A low level of this indicator confirms the company's autonomy.